A Study of BNC210 in Elderly Patients With Agitation

This is a Phase II randomised, double‐blind, placebo‐controlled study assessing the effects of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS). Safety and tolerability of BNC210 will also be assessed. The secondary objectives of the study include evaluation of the effects of BNC210 on global function in patients with agitation as assessed by the Clinical Global Impression Scale (CGI‐S/I). Participants will receive 5 days of blinded treatment followed by 2 days of follow up.